Carlyle Bets Big on AI-Native RCM: What the Knack + EqualizeRCM Deal Means for Your Practice
Carlyle just paid an undisclosed sum to merge two AI-native RCM companies into a single global platform. The signal couldn't be clearer: the era of bolt-on AI features is over. Specialized, agentic revenue cycle management is where the serious money is going.
On May 4, 2026, global investment firm Carlyle (NASDAQ: CG) announced the acquisition of majority stakes in Knack RCM and EqualizeRCM — two U.S. healthcare revenue cycle management providers — to build what it's calling an AI-native, global, multi-specialty RCM platform. Equity comes from Carlyle Asia Partners VI and Carlyle Asia Partners Growth II, underscoring an India-anchored global delivery thesis.
Neither the price nor the revenue figures were disclosed. But the strategic intent is unmistakable: Carlyle is building a scaled consolidator in a fragmented market, and it wants AI at the core — not layered on top.
Who Are Knack and EqualizeRCM?
🔵 Knack RCM
- AI-native, specialty-focused RCM
- Global delivery: U.S., India, Philippines
- Orchestration platform: Workmate
- Serves physician groups, DME, rural hospitals
- Founded by Rajiv Sharma
🟢 EqualizeRCM
- LLM + agentic AI platform
- Proprietary payer enrollment platform
- Bill Smart: denial prediction & avoidance
- Serves hospitals, urgent care, DME
- Founded by Nagi Rao
Together they cover DME, anesthesia, eyecare, behavioral health, rural hospitals, urgent care, and multi-specialty physician groups. That breadth is deliberate — Carlyle is building a platform that can absorb more acquisitions without encountering significant specialty gaps.
Free Daily RCM Intelligence
Denial trends, payer policy moves, vendor intel — delivered every morning. Free.